SEMA3A and breast carcinoma: Inhibited the cell growth in a dose- and time-dependent manner in both breast cancer cell linesAttenuated the invasive capacity and anchorage independent growth by 15 μmIdentifyed 364 hypomethylated CpG sites at day 4 of RSV treatment compared to 990 hypomethylated CpG sites at day 9 of treatmentActivated the tumor suppressor gene SEMA3A epigenetically in breast cancer cellsDecreased the DNMT3A occupancy within SEMA3A promoterIncreased the nuclear factor 1C occupancy at SEMA3A promoterIncreased the SALL3 expression by 2.5-fold upon 9-day treatment of MCF10CA1a cells with 15 μm RSV